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ABSTRACT
Glioblastoma, one of the most aggressive forms of brain cancer, is featured by high
tumor cell motility and invasiveness, which not only fuel tumor infiltration, but also
enable escape from surgical or other clinical interventions. Thus, better understanding
of how these malignant traits are controlled will be key to the discovery of novel
biomarkers and therapies against this deadly disease. Tetraspanin CD151 and its
associated a3β1 integrin have been implicated in facilitating tumor progression across
multiple cancer types. How these adhesion molecules are involved in the progression
of glioblastoma, however, remains largely unclear.Here, we examined an in-house
tissue microarray-based cohort of 96 patient biopsies and TCGA dataset to evaluate
the clinical significance of CD151 and a3β1 integrin. Functional and signaling analyses
were also conducted to understand how these molecules promote the aggressiveness
of glioblastoma at molecular and cellular levels. Results from our analyses showed that
CD151 and a3 integrin were significantly elevated in glioblastomas at both protein and
mRNA levels, and exhibited strong inverse correlation with patient survival (p < 0.006).
These adhesion molecules also formed tight protein complexes and synergized with
EGF/EGFR to accelerate tumor cell motility and invasion. Furthermore, disruption of
such complexes enhanced the survival of tumor-bearing mice in a xenograft model, and
impaired activation of FAK and small GTPases. Also, knockdown- or pharmacological
agent-based attenuation of EGFR, FAK or Graf (ARHGAP26)/small GTPase-mediated
pathways markedly mitigated the aggressiveness of glioblastoma cells. Collectively,
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our findings provide clinical, molecular and cellular evidence of CD151-a3β1 integrin
complexes as promising prognostic biomarkers and therapeutic targets for glioblastoma.

their lateral clustering on the cell surface [18, 20]. It is
of no surprise that CD151 is frequently implicated in
promoting tumor progression by enhancing either α3 or α6
integrin-dependent cellular processes [11, 21, 22]. There is
also evidence that CD151 mediates LB integrin-dependent
activation of multiple signaling pathways [11]. In addition,
there are reports of links between CD151 expression and
tumor grade or patient survival for several cancer types.
Together, these available observations implicate that,
like its associated LB integrins, CD151 is a potential key
player in the progression of glioblastoma. How CD151
and its associated LB integrins are associated with the
aggressiveness of glioblastoma, however, still remains
largely unclear, particularly at the clinical, cellular, and
signaling levels.
Here, we report clinical and functional analyses of
CD151 and its associated α3 integrin in glioblastoma. We
applied annotated tissue microarrays (TMAs) to evaluate
the correlation between the expression of CD151 or α3β1
integrin and clinicopathological parameters, including
tumor grade, IDH1 mutation status, and patient survival.
Additionally, we performed functional studies of multiple
glioma cell lines to assess the impact of CD151 ablation
on glioma aggressiveness, particularly regarding cell
motility and invasiveness. Finally, signaling analyses
were conducted to identify key effectors downstream
of CD151-LB integrin complexes. Results from these
analyses demonstrate that CD151 and α3β1 integrin are
key drivers of glioblastoma aggressiveness, and serve as
independent prognostic markers and promising therapeutic
targets.

INTRODUCTION
Glioblastomas, grade IV gliomas by World Health
Organization (WHO) classification, belong to one of
the most aggressive types of brain cancer [1]. Current
therapeutic management of glioblastomas involves
surgical resection and adjuvant chemoradiation. Despite
advances made in imaging and treatment modalities,
the prognosis of glioblastoma remains very dismal with
five-year patient survival as low as 3% [1]. This fatal type
of brain cancer is characterized by tumor cells with highly
motile and invasive capacities [2]. As such, glioblastoma
is considered an infiltrating disease with a strong tendency
to escape surgical or other therapeutic treatments [1].
The progression and recurrence of glioblastoma
has been strongly linked to the activation of receptor
tyrosine kinases (RTKs) and their signaling pathways
[3]. In particular, the majority of glioblastomas exhibit
activated signaling of epidermal growth factor receptor
(EGFR), which occurs through gene amplification,
activating mutations, and/or receptor overexpression
[4]. Aside from promoting cell proliferation, EGFR
signaling drives the motility and invasiveness of
glioblastoma cells. Unfortunately, the clinical efficacy
of EGFR-specific inhibitors in glioblastoma have fallen
below expectations [5].
There is growing evidence that the malignancy of
glioblastoma is strongly promoted by integrins, a family of
heterodimeric receptors. This class of adhesion molecules
supports cell-extracellular matrix (ECM) interactions,
thereby permitting tumor cell migration and invasion [6].
As members of the integrin family, the laminin-binding
(LB) integrins, including α3β1, α6β1 and α6β4, are highly
expressed in cultured glioblastoma cells [7–9] or a subset
of CD133+ glioma stem cells [10]. They are also implicated
in promoting the migration and invasion of glioblastoma
cells [7, 11]. In contrast, several RGD-binding integrins,
including α5β1 and αvβ3 integrins, appear to promote
tumor cell survival and/or drug resistance of glioblastomas
[12, 13]. These observations raise the likelihood that
integrins, particularly LB integrins, are candidate
regulators of glioblastoma malignancy, and may serve as
biomarkers and/or therapeutic targets for this aggressive
disease.
The pro-malignant function and signaling of
LB integrins are coordinated by members of the
tetraspanin family, including CD151, CD9, CD81, and
CD82 [14–16]. Notably, tetraspanins form tight protein
complexes with LB integrins on the cell surface through
protein-protein or protein-lipid interactions [17–19].
However, only CD151 directly interacts with α subunits
of LB integrins at their extracellular portions, in which it
dictates integrin activation and signaling by influencing
www.impactjournals.com/oncotarget

RESULTS
Clinical association between CD151 and glioma
malignancy
To evaluate the clinical significance of CD151 in
glioma malignancy, we carried out immunohistochemistry
(IHC) analyses with a TMA containing 96 paraffinembedded patient glioma tissues. As shown in Fig. 1A,
CD151 staining was primarily localized on the plasma
membrane of tumor cells and detectable in the cytoplasm.
The number of CD151-positive tumors in the glioblastoma
group, that is, WHO grade IV gliomas, was more than twofold higher than their low-grade counterparts (Fig. 1B).
To evaluate the clinical significance of aberrant CD151
expression, the patient cohort was divided into CD151low (<15% cells positive) and CD151–high groups (≥15%
cells positive), as determined by Cutoff Finder (http://
molpath.charite.de/cutoff/index.jsp) [23]. Our data showed
that patients belonging to the CD151-high group had
29676
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Figure 1: Relationship between CD151, WHO tumor grade, patient survival, and IDH1 gene status in a TMA-based
glioma patient cohort. TMAs harboring 96 patient glioma tissues were subjected to H&E staining and IHC analyses of the CD151

protein. A. Representative images of H&E staining (a, c, e & g) and corresponding CD151 antibody staining (b, d, f & h) of glioma
tissues. B. CD151-positive staining (by percentage) versus tumor grade. P values indicated, *: p < 0.05; **: p < 0.01; ***: p < 0.001.

(Continued )
www.impactjournals.com/oncotarget
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Figure 1: (Continued ) C. Correlation between CD151 expression and overall patient survival (OS); *, p < 0.05. Data shown for analyses of
patient cohorts consisting of (a) WHO grade II-IV gliomas or (b) grade III-IV gliomas or (c) only IV gliomas, i.e., glioblastoma. D. Correlation
between CD151 and status of IDH1 gene from our TMA-based patient cohort (left and middle panels) or TCGA glioblastoma samples
(right panel). For B-D, an in-house TMA-based cohort was stratified into CD151-low and high groups based on IHC staining of CD151 and
corresponding sample sizes indicated. The correlation between CD151 expression and patient survival was evaluated by the Log-rank test.
E. Multi-variant analyses of CD151 as an independent prognostic factor of gliomas. Independent prognostic factors were determined by Cox
proportional hazards analysis of an in-house TMA-based patient cohort (n = 88). TMZ, temozolomide. CI, confidence interval. Scale bar: 50 μm.
www.impactjournals.com/oncotarget
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poorer survival than their counterparts, regardless of how
patient samples were pooled by tumor grade (Fig. 1C).
A similar trend was also detected from our analyses of a
commercial glioma TMA (data not shown).
Because IDH1 gene status is a powerful prognostic
indicator for infiltrative gliomas [24], we also evaluated
the relationship between its mutation status and CD151
expression in our patient cohort. As shown in Fig. 1D,
CD151 protein was significantly lower in gliomas with
mutant IDH1. A similar trend was detected for CD151
mRNA in The Cancer Genome Atlas (TCGA) glioblastoma
dataset. Importantly, a multivariate analysis of our patient
cohort showed that elevated CD151 expression was a better
independent adverse prognostic marker, compared to patient
age, IDH1 status or the treatment with temozolomide, a
standard chemotherapeutic agent (Fig. 1E). Together, these
data demonstrate a strong association between CD151
expression and glioma aggressiveness.

and invasiveness, rather than impacting cell proliferation or
tumor growth.

Functional and clinical links of CD151-associated
α3β1 integrin to glioblastoma malignancy
Tetraspanin CD151 is implicated in mediating diverse
physiological and pathological processes by impacting the
function or signaling of its associated protein complexes,
instead of directly interacting with signaling molecules
[17, 28]. Such complexes are also readily detected by the
abilities of integrins and tetraspanin molecules to incorporate
palmitate and form tetraspanin-enriched membrane
microdomains (TEMs) [17]. Therefore, we conducted [3H]palmitate labeling and co-immunoprecipitation analyses
of multiple glioblastoma cell lines under 1.0% Brij96
condition. Our data showed that CD151 was present in the
protein complexes of α3 and α6 integrins in multiple glioma
cell lines (Fig. 3A). In addition, several other tetraspanins,
including CD9, CD81 and CD82, appeared to exist in the
complexes. The profile of these labeled proteins was also
consistent with our prior studies [16, 29], and supported by
the surface expression of these molecules from our FACS
analyses (Supplementary Fig. S1).
Functional analyses were subsequently performed to
evaluate the contribution of such protein complexes to the
aggressiveness of gliomas. As shown in Fig. 3B, knockdown
of α3 or α6 integrin was as effective as CD151 ablation in
inhibiting EGF-induced invasion of LN229 cells. In contrast,
CD9 knockdown enhanced both basal and EGF-induced
invasion of glioma cells, consistent with its anti-invasive role
as shown in prior studies [25, 28]. In further support of these
observations, we found that the stable knockdown of β1
integrin led to a marked inhibition in the invasion of LN229
cells (Fig. 3C). Together, these data illustrate that CD151
and its associated LB integrins form protein complexes and
cooperate to promote the invasiveness of glioblastomas.
Next, analyses of clinical samples were conducted
to evaluate the link of CD151-associated α3 integrin to the
malignancy of gliomas. As shown in Fig. 4A–B, expression
of α3 integrin was detectable in plasma membrane and
cytoplasmic compartments of tumor cells, and was markedly
elevated in high-grade gliomas including glioblastomas.
Again, by using 15% cells being α3 integrin-positive as a
cutoff value, we found that elevated expression of α3 integrin
was strongly correlated with poor patient survival (p < 0.006)
(Fig. 4C). There was also a significant negative correlation
between the level of this integrin and the mutation status of
IDH1 (Fig. 4D). Protein expression of CD151 and α3 integrin
were strongly correlated in our patient cohort (slope = 11.2 ±
0.93, R2 = 0.58, p < 0.0001) (Fig. 4E). In addition, a similar
association occurred at the mRNA level, according to our
analyses of the TCGA glioma dataset (Fig. 4E). Together,
our analyses of two independent clinical cohorts consistently
suggest that CD151 and α3 integrin act together to promote
the aggressiveness of gliomas.

CD151 promotes glioma cell motility
and invasion
Next, we conducted in vitro analyses to test if
CD151 functionally contributed to the aggressiveness
of gliomas as suggested by our clinical analyses
(Fig. 1). Our FACS analyses indicated that CD151 and
LB integrins were highly expressed across a panel of
glioblastoma cell lines (Supplementary Fig. S1). The
strong expression of other tetraspanins, including CD9
and CD81, was also detected, consistent with a recent
report [25]. According to our Matrigel-based invasion
assay, these tumor cell lines exhibited a wide range of
variation in invasiveness (Fig. 2A). In particular, the
invasive capabilities of LN428, LN308 and LN229
lines increased by 3.5- to 5-fold upon EGF stimulation,
consistent with the strong pro-malignant function of
EGFR in glioblastomas [26, 27]. Because CD151 or its
associated LB integrins have been shown to functionally
collaborate with EGFR in other cancer types [15, 28],
these highly EGF-responsive cell lines were adopted for
subsequent functional analyses.
In the three cell lines most sensitive to EGF (LN229,
LN308, and LN428), CD151 knockdown led to a 2- to
7-fold decrease in the number of tumor cells invading
through the Matrigel after EGF stimulation (Fig. 2B). Also,
EGF-stimulated random cell motility was mostly abolished
upon CD151 ablation when LN229 cells were engaged with
laminin-5, i.e., laminin 332, but not fibronectin (Fig. 2C).
However, CD151 knockdown had only minimal effect on the
proliferation of glioma cells (data not shown). In line with
these in vitro observations, CD151 knockdown extended
the survival of tumor-bearing mice with orthotopic LN229
glioblastoma xenografts (Fig. 2D, p < 0.05), even though
minimal change occurred in tumor growth. These in vitro
and ex vivo observations demonstrate that CD151 promotes
glioblastoma progression by promoting tumor cell motility
www.impactjournals.com/oncotarget
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Figure 2: A role of CD151 in EGF-induced glioblastoma cell motility, invasion, and ex vivo tumor formation. A. EGF-

stimulated invasiveness of cultured glioblastoma cell lines. Glioblastoma cell lines including LN827, LN428, LN308, LN229, U87 and LN373
were subjected to an invasion assay with respect to the presence and absence of EGF. 1.0 × 105 tumor cells were placed on the top of a Matrigelcoated insert in a 24-well plate and allowed to invade for 17–20 hrs before being fixed. Number of invaded cells is shown (mean ± SEM, n = 3).

(Continued )
www.impactjournals.com/oncotarget

29680

Oncotarget

Figure 2: (Continued ) B. Effect of CD151 knockdown (KD) on the invasion of LN308 and LN229 cells (fold change ± SEM, n = 3).
The efficiency of stable knockdown of CD151 was assessed by FACS analyses (see Supplementary Fig. S2). C. Effect of CD151 KD on
glioma cell motility. Random cell motility was measured for LN229 cells with or without CD151 KD. The analyses were conducted in
triplicate and average distance traveled by individual cells were estimated. A total of 25–35 individual cells per treatment were tracked. For
A-C, EGF: 10 ng/ml. D. Xenograft analyses of CD151 ablation on tumor growth. Mice injected with control or CD151 knockdown LN229
cells at 10 animals per group monitored over the indicated periods of times. (a) Survival curve of tumor-bearing mice. The p-value was
obtained by Log-rank test; (b) Change in the bioluminescence of injected mice.

CD151-α3β1 integrin complexes drive tumor cell
motility and invasion via FAK activation

examined the signaling link of FAK activation to CD151integrin complex-mediated glioma aggressiveness. Our
data showed that the stable knockdown of CD151 caused
a delay or decrease in the phosphorylation of FAK-Y397
residue induced by the engagement of α3β1 integrin and
its physiological ligand, laminin-5, during the transient

Recent studies have implicated that FAK is a
putative driver of glioma malignancy and acts downstream
of CD151-integrin complexes [15, 28]. Hence, we
www.impactjournals.com/oncotarget
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Figure 3: The pro-invasive function of CD151-associated protein complexes in glioblastoma cells. A. Co-immunoprecipitation
of CD151 and LB integrins. Lysates of [3H]-palmitate-labeled glioma tumor cells were subjected to immunoprecipitation with the indicated
antibodies, followed by radiographic detection. Left panel, short exposure; right panel, long exposure. B. Impact of disrupting CD151,
and its associated integrins and tetraspanin molecules on the invasion of glioma cells. LN229 cells were treated with scramble (control) or
siRNA against CD9, CD151, α3 and α6 integrins. Fold changes were calculated relative to the number of invaded cells in the group treated
with control siRNA in the absence of EGF stimulation.

(Continued )
www.impactjournals.com/oncotarget
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Figure 3: (Continued ) C. Effect of stable knockdown of β1 integrin on the invasion of LN229 cells. EGF: 10 ng/ml. B-C The efficiency
of tetraspanin or integrin knockdown was estimated by immunoblotting or FACS analysis (see Supplementary Fig. S3, panels A-B).

spreading of either LN229 or LN308 cells (Fig. 5A). In
addition, FAK knockdown reduced the EGF-induced
invasion of LN229 and LN308 cells by 2.3- to 3.5-fold
(Fig. 5B), respectively. In line with these observations,
EGF-induced cell motility was also markedly impaired
when FAK was inhibited by the use of a small moleculebased inhibitor, TAE226 [30]. Such inhibition was
nearly equally effective as CD151 knockdown (Fig. 5C).
Moreover, the involvement of EGFR in the motility of
glioma cells was independently validated by our analyses
with two clinically relevant EGFR inhibitors, lapatinib/
Tykerb and gefitinib/Iressa (Fig. 5D). Taken together,
these results illustrate that FAK promotes the aggressive
traits of gliomas by acting downstream of CD151-integrin
complexes and EGFR.

complexes. As shown in Fig. 6B, disruption of DOCK180
impaired motility of LN229 cells on fibronectin but not
laminin-5 substrate. A similar effect was found when
ELMO1, another motility-related adaptor molecule
strongly implicated in the aggressiveness of gliomas [33],
was knocked down (Fig. 6C). However, only disruption
of Graf (ARHGAP26) led to a marked decrease in the
motility of LN229 cells on laminin-5, regardless of
EGF stimulation (Fig. 6C). Together, these observations
indicate a crucial role of the Graf (ARHGAP26)/Rac1/
Cdc42 axis, not DOCK180 or ELMO1, in CD151-α3
integrin complex-mediated signaling in glioblastoma.

Graf (ARHGAP26) as a key downstream effector
of CD151-α3β1 integrin complex signaling

Results from our studies support a close link
between CD151-α3β1 integrin complexes and the
aggressiveness of glioblastomas. Our analyses of TMAbased glioma patient cohort as well as TCGA glioma
dataset consistently indicate that the expression of CD151
or α3β1 integrin is strongly correlated with tumor grade,
IDH1 gene status, and patient survival. Our biochemical
analyses reveal the presence of CD151-α3β1 integrin
complexes in glioblastoma cells. Disruption of CD151 or
α3β1 integrin markedly impairs EGF/EGFR-evoked tumor
cell motility and invasiveness. At the signaling level,
CD151-α3β1 integrin complexes cooperate with EGFR
to activate FAK- and Graf (ARHGAP26)/Rac1/Cdc42

DISCUSSION

Integrins have recently been implicated in
promoting the motility of glioma cells via activation of
multiple small GTPases including Rac1 and Cdc42 [31,
32]. Thus, we sought to determine whether a similar link
existed in glioma cells. Our data showed that CD151
knockdown markedly impaired the activation of Rac1
or Cdc42 GTPases upon engagement of α3 integrin with
laminin-5 in LN229 or LN308 cells (Fig. 6A). Next, we
sought to identify which specific GDP/GTP exchange
factors or RhoGAPs acted downstream of CD151-integrin
www.impactjournals.com/oncotarget
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axis-mediated pathways. Together, these findings provide
strong clinical, cellular and molecular evidence that
CD151-α3β1 integrin complexes and associated pathways
are crucial players in the progression of glioblastoma or
other malignant gliomas (Fig. 6D).

(Figs. 1, 4). These results are also in accord with recent
reports of CD151 expression in glioblastomas [34, 35].
Moreover, our data indicate a significant concordance in
the expression of CD151 and α3β1 integrin in our patient
cohort and TCGA gliomas (Fig. 4E). As such, our findings
support CD151 and α3β1 integrin as potential biomarkers
for glioblastoma.
It is of clinical significance to know how expression
of CD151 or α3β1 integrin is markedly elevated in
glioblastomas at both the mRNA and protein levels. Based
on prior biochemical analyses, the increase in CD151
protein is potentially attributable to the simultaneous
elevation in α3 integrin [18]. However, it is still unclear
as to the mechanism of CD151 mRNA upregulation in
glioblastomas. Our analyses of TCGA glioblastomas

Aberrant expression of CD151 and α3β1 integrin
as independent prognostic factors
The current study provides strong clinical evidence
for the close link between CD151 or its associated α3β1
integrin and the malignancy of human glioblastoma.
Our TMA-based analyses reveal significant correlation
between CD151 or its associated α3β1 integrin and
tumor grade, patient survival, and IDH1 gene status

Figure 4: Relationship between α3 integrin, WHO tumor grade, IDH1 gene status, patient survival and CD151
expression in a TMA-based glioma patient cohort and TCGA glioblastomas. A. Representative images of H&E

(a, c, e, g) and IHC staining (b, d, f, h) of an in-house glioma TMA as described in Figure 1. IHC analyses were conducted with a
polyclonal antibody against α3 integrin. a-b, grade II; c-d grade II; e-f, grade III; g-h, grade IV or glioblastoma. P values indicated.

(Continued )
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Figure 4: (Continued ) B. A plot of percentages of α3 integrin-positive staining versus tumor grade. P values are indicated (*p < 0.05;
**p < 0.01; ***p < 0.001). C. Association of α3 integrin and overall patient survival (OS) in WHO grade III-IV gliomas. The patient cohort
was divided into low and high α3 integrin expression groups. The cutoff was at ≥ 3 IHC staining of α3 integrin. The significance of the
correlation between α3 integrin and patient’s survival was assessed by the Log-rank test. D. The association between CD151 expression and
status of IDH1 gene from IHC or TCGA database analyses. E. Correlation between CD151 and α3 integrin expression in the TMA cohort
of grade II-IV gliomas at protein level (left panel) or at mRNA level (right panel). The mRNA expression of these genes was obtained in
the external TCGA glioblastomas dataset. Sample sizes indicated. Scale bar: 50 μm.

reveal minimal change in the copy number of CD151 or α3
integrin gene (data not shown), implicating a mechanism
other than gene amplification or copy gain. Meanwhile,
there is evidence that CD151 expression in gliomas is
regulated by micro-RNAs or epigenetic regulation [34,
36]. In particular, mutation of IDH1 gene in gliomas has
been shown to influence the methylation of a number of
pro-malignant genes [3, 37], and is strongly associated
with CD151 expression in our patient cohort (Fig. 1D).
Thus, there is a likelihood that the aberrant expression of
CD151 or α3β1 integrin in high-grade gliomas may result
from epigenetic regulation.

motility and invasiveness (Figs. 2, 5, 6). These findings
are also in line with recent functional studies of these
molecules in glioblastomas [7–9, 39]. Given the high
expression of multiple laminin isoforms in glioblastoma
cells [8, 9, 40], CD151-α3β1 integrin complexes may
act in an autocrine fashion. This notion is also supported
by recent observations of α3β1 integrin function across
multiple cancer types [41]. Moreover, because normal
brain tissues are highly enriched in laminins [42], the
pro-malignant roles of CD151-α3β1 integrin complexes
in glioblastomas are likely strengthened by the tumor
microenvironments.
Our data also implicate that the impact of CD151α3β1 integrin complexes on the malignant behaviors of
glioblastomas may occur in the context of TEMs. Notably,
functional loss of tetraspanin CD9 led to a marked
increase in EGF-stimulated tumor cell invasion, consistent
with recent analyses of CD81 and its associated EWI-2
protein complexes in gliomas [25]. Intriguingly, CD151
knockdown in multiple glioblastoma lines had minimal
effect on the surface expression of its associated partners,
as determined by our FACS analyses (Supplementary
Fig. S2). Perhaps, CD151 promotes the clustering of its

Functional contribution of CD151 and α3β1
integrin to glioblastoma malignancy
Although the RGD-based integrins, such as
α5β1 integrin, are shown to promote survival and drug
resistance of glioblastoma cells [12, 38], disruption of
CD151 or α3β1 integrin appears to have minimal influence
on the proliferation or survival of glioblastoma cells (data
not shown). Rather, CD151 and α3β1 integrin drive the
aggressiveness of glioblastoma by accelerating tumor cell
www.impactjournals.com/oncotarget
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associated integrin molecules on the cell surface [20, 28].
How CD151 and CD9 molecules within the same protein
complexes or TEM confer opposing cellular or signaling
functions, however, still remains a mystery.
Of note, CD151 may also drive glioblastoma
malignancy by affecting the stemness property of glioma
cells. This tetraspanin has recently been linked to the
dynamics of tumor-initiating or progenitors cells [43, 44].
Also, CD151-associated α3 and α6 integrins are shown
to enhance the aggressive behaviors of cancer stem cells
[7, 10]. Thus, identification of a stem cell-related link will
shed new light on the importance of CD151-LB integrin
complexes or associated TEMs in glioblastoma malignancy.

[21, 28]. In addition, our observation of the activation
of FAK as reflected by the enhanced phosphorylation
of Y397 residue upon the engagement of laminin-5 and
CD151-integrin complexes is in line with the promalignant role of this non-receptor tyrosine kinase in
glioblastomas [45]. Beside the phosphorylation of Y397
residue, FAK may convey CD151-integrin complexmediated signaling through the phosphorylation of Y925
residue upon EGF stimulation [46, 47]. Furthermore,
we found that CD151-α3β1 integrin complexes signal
through Graf (ARHGAP26)/small GTPase-dependent
pathways in glioblastoma cells (Fig. 6). In contrast to a
prior report on ELMO1, a regulator of GTPase activation
and glioma cell motility [33], our study suggest that
the crosstalk between the CD151-integrin complexes
and RTKs converge at ARHGAP26, consistent with its
link to the EGFR-mediated cell motility and signaling
[48]. Collectively, our data suggest that CD151-α3β1
integrin complexes and EGFR converge at FAK and Graf
(ARHGAR26) to drive the motility and invasiveness of
glioblastoma.
The contribution of CD151 and associated LB
integrins to glioma aggressiveness may not be completely
dependent on their crosstalk with the EGFR pathway.

Signaling role of CD151-α3β1 integrin complexes
in glioblastomas
The strong cooperation or synergy between CD151LB integrins complexes and EGFR in glioblastomas
revealed by our study (Figs. 3–6) is of high translational
significance, as aberrant activation of this RTK occurs in
>70% gliomas [4]. This type of signaling crosstalk is also
consistent with our recent analyses of CD151 function
in other malignancies, including breast and skin cancers

Figure 5: Activation of FAK in glioma cells by CD151-α3β1 integrin complexes and their crosstalk with EGFR. A. Effect
of CD151 ablation on integrin-dependent phosphorylation of FAK-Y397 residue. LN229 or LN308 cells with or without stable CD151 KD
were transiently placed onto laminin-5 substrate for the indicated periods of time, followed by lysing in RIPA buffer and immunoblotting. Top
panel, immunoblotting of total or phosphorylated FAK. Bottom panel, ratios of FAK-Y397/Total FAK proteins determined by densitometry.
B. The impact of FAK knockdown on the invasion of either LN229 or LN308 glioma cells. FAK was knocked down via siRNA and
confirmed by immunoblotting (see Supplementary Fig. S3, panel C).

(Continued )
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Figure 5: (Continued ) C–D. The impact of FAK or EGFR inhibition on EGF-mediated random tumor cell motility in control and
CD151 KD LN229 cells. Inhibition of FAK and EGFR was carried out by using TAE226 or Lapatinib or Gefitinib at 0.1 μM or 0.5 μM.

In fact, CD151 and LB integrins have been shown to
collaborate with multiple oncogenic RTKs (e.g., c-Met
and ErbB2) or Ras/MAPK pathways [15, 28, 49] or Mycdriven network [50]. As these oncogenic events frequently
occur in glioblastoma [26, 27, 51], the cooperation
between CD151-α3β1 integrin complexes and EGFR
detected in the current study may only reflect part of broad
contributions of such complexes to the aggressiveness of
such disease. However, it is unlikely that the signaling
effect of CD151–integrin complex detected in the current
www.impactjournals.com/oncotarget

study is attributed to their impact on the EGFR activation,
particularly its autophosphorylation, according to our
recent studies [15, 52].
It is worth noting that the pro-malignant function
of CD151-integrin complexes in glioblastoma occurs
in the context of cell-ECM interaction, consistent with
prior studies in other cancer types [52, 53]. However,
such adhesion molecules are also capable of suppressing
tumorigenesis, particularly in the presence of intact cellcell contact or E-cadherin [54, 55].
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Oncotarget

Implications of CD151-α3β1 integrin complexes
and associated pathways as therapeutic targets

roles of CD151 or α3β1 integrin are readily disrupted
by administration of function-blocking monoclonal
antibodies, such as 1A5 or Tsr151 for CD151, and IIF5
or P1B5 for α3 integrin [21]. The functional disruption
of these molecules is also achievable through inhibition
of downstream signaling, such as FAK activation (Fig. 5).
Given the emerging link of these molecules to the

Results from the present study strongly support
the prognostic and therapeutic potential of CD151α3β1 integrin complexes and their associated pathways
for glioblastoma. Experimentally, the pro-malignant

Figure 6: A functional link between CD151-LB integrin complexes and the GRAF/Small GTPase signaling axis. A. Effect

of CD151 ablation on integrin-dependent activation of small GTPase Rac1 and Cdc42 in LN229 and LN308 cells. Control and CD151 KD
cell were detached and transiently engaged with laminin-5 substrate for the indicated periods of time, followed by lysing in RIPA buffer and
immunoblotting. Top panel, immunoblotting of Rac1 in GTP-bound form or present in cell lysates. Bottom panel, indices of GTP-bound
Rac1 protein determined by densitometry.

(Continued )
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Figure 6: (Continued ) B-C. Effect of DOCK180, ELMO1, and GRAF/ARHGAP26 knockdown on integrin-mediated
motility of LN229 glioma cells. The average distance traveled by tumor cells was calculated. Values: mean ± SEM (n = 15).
Efficiency of DOCK180, ELMO1, and GRAF/ARHGAP26 knockdown was assessed by immunoblotting (see Supplementary
Figure S3, panels D-E). EGF: 10 ng/mL. D. A schematic illustration of a working model of CD151-α3β1 integrin complexes
in glioblastoma.
stemness of glioblastoma [7, 10], targeting CD151-LB
integrin complexes may also provide an effective means
against tumor recurrence.
In summary, our study demonstrates that CD151
and its associated α3 integrin are markedly elevated in
malignant gliomas, and synergize with EGFR-dependent
signaling pathways to drive the aggressive behaviors of
glioblastoma cells. As such, our findings provide crucial
evidence of CD151-integrin complexes and associated
pathways as prognostic markers and therapeutic targets
for glioblastoma or other aggressive gliomas.

and FITC conjugated) was from Biosource (San Diego,
CA). The monoclonal antibodies to CD81 (M38) or
integrin α2 (IIE10), α3 (X8), α6 (GÖH3), β1 (TS2/16), and
β4 (3E1) were described elsewhere [15, 16]. Antibodies to
FAK and Y397-phosphorylated FAK were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to
small GTPases (Rac1 and Cdc42) were obtained from Cell
Signaling Technology (Danvers, MA). Small moleculebased inhibitors against FAK (TAE226) or EGFR/ErbB2
(lapatinib or gefitinib) were described in a prior study [15].
Antibodies used for IHC analyses of CD151 and
α3 integrin were obtained from Leica Microsystems
(Lawrenceville, GA) or prepared in-house [54]. IDH1
mutation status was examined by using an anti-R132H
IDH1 antibody (HistoBioTec, Miami Beach, FL). Human
glioblastoma cell lines LN827, LN428 and LN308 were
obtained from Dr. Erwin Van Meir (Emory University,
Atlanta, GA) [56]. LN229, LN373, and U87 lines were
purchased from ATCC (Manassas, VA). For xenograft

MATERIALS AND METHODS
Antibodies, reagents, and cell cultures
CD151 monoclonal antibodies include 5C11, 1A5
and FITC-conjugated IIG5a (GeneTex, San Antonia, TX).
Anti-CD9 monoclonal antibody MM2/57 (unconjugated
www.impactjournals.com/oncotarget
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analysis, LN229 cells were engineered to express
luciferase as previously described [57]. No authentication
was conducted on all cell lines used in the current study.
All cell lines were cultured in DMEM or RPMI-1640
supplemented with 10% fetal bovine serum, 10 mmol/L
HEPES, and antibiotics (Invitrogen, Carlsbad, CA).
All cultures were maintained at 37°C in a humidified
atmosphere of 5% CO2. EGF was obtained from UBI
(Lake Placid, NY). Matrigel and fibronectin were obtained
from BD Biosciences (San Jose, CA). Laminin-5 was
prepared for the condition medium of A431 carcinoma
cells as previously described [30].

were detached using non-enzymatic EDTA-containing
dissociation buffer (Life Technologies, Grand Island, NY).
Cells were then suspended in serum-free DMEM with
0.02% bovine serum albumin, and added to trans-well
chambers containing 8-μm membranes pre-coated with
Matrigel (BD Biosciences). Chamber bottoms contained
serum-free medium with or without presence of 10 ng/mL
EGF. After invasion through Matrigel (12–18 h, 37°C),
membranes were washed, dried, fixed, and stained with
Giemsa (Sigma-Aldrich, St. Louis, MO). Proliferation of
human glioblastoma cells was evaluated by MTT assay.
Fold changes were calculated relative to the control
without the presence of a stimulant.

Transient and stable knockdown of tetraspanins
and integrins using siRNA and shRNA

Immunoprecipitation, [3H]-palmitate labeling,
and signaling assays, and immunoblot analyses

For all transient knockdowns, on-target siRNAs
were purchased from Dharmacon (Lafayette, CO) and
delivered to tumor cells using Lipofectamine-2000
(Invitrogen). For stable knockdown, human CD151 or
β1 integrin oligos were cloned into lentivirus expression
vector plenti-U6BX and verified by DNA sequencing and
mutagenesis analyses as previously described [28]. The
infected cells were sorted on flow cytometry by double
sorting with GFP and with specific monoclonal antibodies
for selection of stable CD151 or β1 integrin knockdown
cell lines.

For metabolic labeling, siRNA-treated cells (80–90%
confluent) were washed in PBS, serum starved (3–4 h),
pulsed for 1–2 h in medium containing 0.2 to 0.3 mCi/mL
[3H]-palmitic acid plus 5% dialyzed FBS, and then lysed
in 1% Brij-96 for 5 h at 4oC. Immunoprecipitation
and detection of [3H]-palmitate-labeled proteins were
completed as previously described (12, 30, 31). To assess
protein phosphorylation, cells were lysed in RIPA buffer
containing 1% Triton X-100, 1% deoxycholate, and
0.1% SDS.
For signaling analyses, cells were seeded onto
6-well plates (2 × 105 cells per well) and starved overnight
prior to stimulation. Cells were lysed in RIPA buffer
supplemented with 1 mM Na3VO4, PMSF and protease
inhibitor cocktail [30]. Protein concentrations were
quantified by use of DC Protein Assay Kit (Bio-Rad,
Hercules, CA). Then phosphorylated proteins were either
immunoprecipitated and blotted with anti-phosphotyrosine
antibody (4G10, UBI) or directly blotted in cell lysates
using phospho-specific antibodies. Rac1 activation was
assessed with a glutathione S-transferase (GST)-PBD pulldown assay kit (UBI).
Immunoblotting or Western analyses were
conducted by separating equal amounts of proteins on
SDS-PAGE and transferring samples onto a nitrocellulose
membrane prior to blotting detection with the indicated
antibodies. For evaluation of the differences in protein
expression, ratios of densitometry values of individual
protein to β-actin were calculated. These values were
subsequently divided by the smallest value within the
group to obtain a fold change.

Cell sorting and FACS analyses
Cell sorting was carried out to obtain glioblastoma
cell lines infected with lentivirus-expressing control or
CD151-specific shRNA as previously described [28].
Virus-infected tumor cells were initially stained with
anti-CD151 monoclonal antibodies (5C11) and APCconjugated secondary antibodies on ice, followed by twoway sorting on flow cytometry at our local core facility.
For FACS analyses of the expression of cell surface
molecules, tumor cells were stained with the indicated
primary monoclonal antibodies, followed by fluorescenceconjugated secondary antibodies prior to analyses on flow
cytometry. For each FACS analyses, a total of 5–10 ×
103 cells were analyzed and mean fluorescence intensity
values were calculated.

Tumor cell motility, invasion, and
proliferation assays
Analyses of random cell motility were conducted by
imaging live tumor cells at 20 min intervals for 12 h with
a Nikon Automated Eclipse Ti-E inverted microscope and
an OKALAB incubator equipped with a heater and gas
mixer constant at 37°C and 5% CO2. Nikon NIS-Elements
Advanced Analysis Software was employed to estimate
distance traveled by tumor cells as described in our prior
study [15]. For analyses of tumor cell invasion, cells
www.impactjournals.com/oncotarget

Tissue microarrays of glioblastomas and IHC
analyses
A set of tissue microarrays (TMAs) were prepared
in-house using archived formalin-fixed, paraffinembedded gliomas as previously described [45]. A total
of 96 cases comprised the TMAs, including 9 WHO
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grade II astrocytomas, 11 grade III astrocytomas, 12
anaplastic grade III oligodendrogliomas, 16 grade II
oligodendrogliomas, and 47 grade IV glioblastomas.
A commercial TMA of glioblastomas was also purchased
from US Biomax (Rockville, MD). IHC staining of
paraffin-embedded TMAs was performed as previously
described [45]. In brief, secondary antibodies were
EnVision labeled polymer-HRP (horseradish peroxidase)
anti-mouse or anti-rabbit as appropriate. Staining
was visualized using 3, 3′-diaminobenzidine (DAB)
chromogen (Dako, Copenhagen, CA). The TMAs stained
with antibodies against CD151 were digitally quantified
via ScanScope XT whole slide scanner, followed by
analysis with Aperio Spectrum Version 11.2.0.780
software. For technical reasons, the TMA cores stained
with α3 integrin were difficult to reliably score digitally,
so instead they were visually semi-quantified by C.H.
on a relative scale from 0 to 3 (0 = negative, 1 = weak,
2 = intermediate, 3 = strong).
For both digital and visual scoring, results from all
3 cores were averaged together to produce a final score for
a tumor. The scoring of immunostaining was evaluated on
the basis of staining intensity and percentages of positively
stained areas.

post-hoc Dunn’s test, as appropriate. Correlation between
CD151 and α3 integrin expression was measured via linear
regression. Survival differences were compared via logrank (Mantel-Cox) test. Multivariate survival analysis was
done via Cox proportional hazards survival regression.
Statistical significance was reached when p < 0.05. All
analyses were done via GraphPad software (La Jolla,
CA), except for the Cox proportional hazards survival
regression which was done using http://statpages.org/.
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